CHRONIC MYELOID-LEUKEMIA TREATMENT WITH RECOMBINANT INTERFERON-ALPHA-2

A trial has been conducted of recombinant alpha2-interferon (reaferon) used in 32 patients with Rh'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance of reaferon basing on the immunological data (detection of antireaferon neutrolizing antibodies). The authors propose of combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.